Drugs / Telmisartan/S-Amlodipine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02047175 | Feb → Mar 2014 | hyperlipidemia, hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Chong Kun Dang Pharmaceutical | Results 종근당, 유럽고혈압학회서 '텔미누보 20/1.25mg' 3상 임상 결과 발표 ckdpharm.com ↗
연구 결과 텔미누보 20/1.25mg은 기존 단일제 대비 우수한 혈압강하 효과를 나타냈으며, 안전성과 내약성 또한 단일제와 유사한 수준으로 확인됐다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Chong Kun Dang Pharmaceutical | 종근당, 유럽고혈압학회서 '텔미누보 20/1.25mg' 3상 임상 결과 발표 ckdpharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Telmisartan/S-Amlodipine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02047175 ↗ |
| Route | Oral | “Telmisartan/S-Amlodipine 40/2.5mg 2T PO, QD for 9days” NCT02047175 ↗ |